Technical glitches, delay in issue of passes leave many stranded at border
Migrants complain officials are delaying their entry citing silly reasons and technical formalities
Migrants complain officials are delaying their entry citing silly reasons and technical formalities
Possibilities in auxiliary technique combinations with small- and wide-angle X ray scattering are described, as well as more complicated sample environments used in X-ray and neutron scattering.
This feature article reviews the control and understanding of nanoparticle shape from their crystallography and growth. Particular emphasis is placed on systems relevant for plasmonics and catalysis.
Are synchrotrons needed for innovation in industry? What can scientists at large-scale facilities offer for R&D in industry? Is the comfort of life profiting from research?
Although the success of molecular-replacement techniques requires the solution of a six-dimensional problem, this is often subdivided into two three-dimensional problems. REMO09 is one of the programs which have adopted this approach. It has been revisited in the light of a new probabilistic approach which is able to directly derive conditional distribution functions without passing through a previous calculation of the joint probability distributions. The conditional distributions take into account various types of prior information: in the rotation step the prior information may concern a non-oriented model molecule alone or together with one or more located model molecules. The formulae thus obtained are used to derive figures of merit for recognizing the correct orientation in the rotation step and the correct location in the translation step. The phases obtained by this new version of REMO09 are used as a starting point for a pipeline which in its first step extends and refines the molecular-replacement phases, and in its second step creates the final electron-density map which is automatically interpreted by CAB, an automatic model-building program for proteins and DNA/RNA structures.
In recent years, there have been numerous efforts worldwide to develop the synchrotron X-ray scanning tunneling microscopy (SX-STM) technique. Here, the inauguration of XTIP, the world's first beamline fully dedicated to SX-STM, is reported. The XTIP beamline is located at Sector 4 of the Advanced Photon Source at Argonne National Laboratory. It features an insertion device that can provide left- or right-circular as well as horizontal- and vertical-linear polarization. XTIP delivers monochromatic soft X-rays of between 400 and 1900 eV focused into an environmental enclosure that houses the endstation instrument. This article discusses the beamline system design and its performance.
An energy resolution of <10 µeV for the measurement of phonon energy change is achieved with the inelastic neutron spin echo technique on a conventional neutron triple-axis spectrometer.
The newfound world, GJ1214b, is about 6.5 times as massive as the Earth. Its host star, GJ1214, is a small, red type M star about one-fifth the size of the Sun. GJ1214b orbits its star once every 38 hours at a distance of only 1.3 million miles. Astronomers estimate the planet's temperature to be about 400 degrees Fahrenheit. Although warm as an oven, it is still cooler than any other known transiting planet because it orbits a very dim star.
The post Astronomers Find Super-Earth Using Amateur, Off-the-Shelf Technology appeared first on Smithsonian Insider.
Finding this stellar relic wasn’t easy. It is 60,000 times dimmer than the faintest star visible to the unaided eye. The team also had to distinguish it from many surrounding stars that aren’t so old. Just like an archaeological dig, the hunt succeeded through a combination of patience and clever use of technology.
The post Ancient star discovered through patience and clever use of technology appeared first on Smithsonian Insider.
Eric Silver of SAO is pursuing innovative and interdisciplinary uses of his technique for chemical imaging at the cellular level.
The post Technology developed for X-ray astronomy is being adapted to study cancer cells appeared first on Smithsonian Insider.
Using 2-dimensional and 3-dimensional CT scans, Natural History Museum anthropologists found that the brain and major organs were removed and rolls of linen filled out the abdominal cavity. This mummification method is evidence of superior embalming, indicating a person of higher status.
The post Video: A mummy ‘grows’ with CT scans and 3D digital technology appeared first on Smithsonian Insider.
The Life and Morals of Jesus of Nazareth, more commonly known as the Jefferson bible, is a volume created by Thomas Jefferson containing passages he […]
The post Unlocking the mysteries of Jefferson’s bible with high-tech analysis and microscopic testing appeared first on Smithsonian Insider.
Now, for the first time scientists at the Smithsonian’s Museum Conservation Institute have developed a fast and reliable method to date silk.
The post New technique for dating silk developed by Smithsonian conservation team appeared first on Smithsonian Insider.
In 2011, scholars from three institutions—National Museum of American History Curators Carlene Stephens and Shari Stout, Library of Congress Digital Conversion Specialist Peter Alyea and Lawrence Berkeley National Laboratory Scientists Carl Haber and Earl Cornell—came together in a newly designed preservation laboratory at the Library of Congress to recover sound from those recordings made more than 100 years ago.
The post Digital technology allows Alexander Graham Bell’s 1880s disc recordings to be played again appeared first on Smithsonian Insider.
With the tap of a finger, keepers are introducing the Zoo’s six orangutans to iPads, which provide unique stimuli.
The post National Zoo orangutans turn high-tech with apps for apes appeared first on Smithsonian Insider.
The largest fully preserved great ape collection in the world is about to make its online debut.
The post Unlocking secrets–technology allows scientists to peer inside great apes appeared first on Smithsonian Insider.
Studies show that on average, the weight of cremated remains for men is about 7.13 pounds (plus or minus 1.2 pounds) and for women, 4.9 […]
The post Hi-Tech Analysis Cracks Curious Case of Contaminated Cremains appeared first on Smithsonian Insider.
Fetching close to $1,500 per pound, ivory ranks fourth in black-market traded items just behind illegal drugs, weapons, and humans. Governments across the globe are […]
The post New technique may help authorities quickly ID real and fake ivory products appeared first on Smithsonian Insider.
For more than 60 years, researchers have tried to successfully cryopreserve (or freeze) the embryo of zebrafish, a species that is an important medical model […]
The post Gold nanotechnology and lasers used to successfully freeze fish embryos appeared first on Smithsonian Insider.
Cooper Hewitt, Smithsonian Design Museum, the only museum in the U.S. devoted exclusively to design, reopens after a 3-year makeover with 60 percent more exhibition […]
The post Smithsonian Design Museum in NYC Reopens with High Tech Makeover appeared first on Smithsonian Insider.
The Windows Defender Browser Protection tech support scam is a fake web site alert that states that Windows Defender Browser Extension detected someone to hack your bank account.
This article was published first at Remove the Windows Defender Browser Protection Tech Support Scam
Full Text:
The same artificial intelligence technique typically used in facial recognition systems could help improve prediction of hailstorms and their severity, according to a new, National Science Foundation-funded study. Instead of zeroing in on the features of an individual face, scientists trained a deep learning model called a convolutional neural network to recognize features of individual storms that affect the formation of hail and how large the hailstones will be, both of which are notoriously difficult to predict. The promising results highlight the importance of taking into account a storm's entire structure, something that's been challenging to do with existing hail-forecasting techniques.
Image credit: Carlye Calvin
Full Text:
National Science Foundation (NSF)-funded researchers from North Carolina State and Elon universities have developed a technique that allows them to remotely control the movement of soft robots, lock them into position for as long as needed and later reconfigure the robots into new shapes. The technique relies on light and magnetic fields. "By engineering the properties of the material, we can control the soft robot's movement remotely; we can get it to hold a given shape; we can then return the robot to its original shape or further modify its movement; and we can do this repeatedly. All of those things are valuable, in terms of this technology's utility in biomedical or aerospace applications," says Joe Tracy, a professor of materials science and engineering at NC State and corresponding author of a paper on the work. In experimental testing, the researchers demonstrated that the soft robots could be used to form "grabbers" for lifting and transporting objects. The soft robots could also be used as cantilevers or folded into "flowers" with petals that bend in different directions. "We are not limited to binary configurations, such as a grabber being either open or closed," says Jessica Liu, first author of the paper and a Ph.D. student at NC State. "We can control the light to ensure that a robot will hold its shape at any point."
Image credit: Jessica A.C. Liu
Source: Streetwise Reports 05/06/2020
Arcturus Therapeutics Holdings' arrangement is explained and commented on in an H.C. Wainwright & Co. report.In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."
Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.
As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.
Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.
Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.
Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."
H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.
Sign up for our FREE newsletter at: www.streetwisereports.com/get-newsDisclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020
Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.
I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.
Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.
The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.
The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.
H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.
( Companies Mentioned: ARCT:NASDAQ, )